Compare EPAC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | EVO |
|---|---|---|
| Founded | 1910 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 778.3M |
| IPO Year | 1994 | 2007 |
| Metric | EPAC | EVO |
|---|---|---|
| Price | $37.13 | $1.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $48.00 | $7.00 |
| AVG Volume (30 Days) | ★ 332.2K | 46.0K |
| Earning Date | 03-25-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ 8.97 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $616,899,000.00 | N/A |
| Revenue This Year | $5.60 | $1.37 |
| Revenue Next Year | $5.56 | $10.05 |
| P/E Ratio | $29.83 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $32.35 | $1.89 |
| 52 Week High | $45.00 | $4.27 |
| Indicator | EPAC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 40.38 |
| Support Level | $36.79 | $1.90 |
| Resistance Level | $37.77 | $2.20 |
| Average True Range (ATR) | 0.69 | 0.05 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 58.46 | 19.35 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.